Previous 10 | Next 10 |
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its firs...
2023-04-06 16:23:10 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) on Thursday disclosed in an SEC filing a prospectus for a proposed mixed shelf offering to raise $250 million. The company expects to offer debt securities, common stock, preferred stock, units, and warrants under t...
2023-03-13 04:02:42 ET In wake of the bank's collapse with turmoil surrounding Silicon Valley Bank, several smaller pharma, biotech companies and health care equipment have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). Among the biotec...
Syros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Conference Call March 02, 2023 08:30 AM ET Company Participants Karen Hunady - Director-Investor Relations & Corporate Communications Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer ...
Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q4 GAAP EPS of -$0.17 beats by $1.13 . Cash, cash equivalents and marketable securities as of December 31, 2022 were $202.3 million, as compared with $143.4 million on December 31, 2021. Based on its current plans, Syro...
-- Commenced randomized portion of SELECT-AML-1 trial, with initial data expected in 4Q 2023 -- -- Received FDA Fast Track designation for tamibarotene for the treatment of HR-MDS -- -- On-track to complete enrollment in SELECT-MDS-1 trial in 4Q 2023, with pivotal data expecte...
Gainers: Okta ( OKTA ) +13% . Kezar Life Sciences ( KZR ) +7% . Esperion Therapeutics. ( ESPR ) +6% . Syros Pharmaceuticals ( SYRS ) +5% . ImmunityBio ( IBRX ) +5% . Losers: Funko ( FNKO ) -27% . ZimVie ( ZIMV ...
Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is -$1.36 (-257.9% Y/Y) and the consensus Revenue Estimate is $3.85M (-95.1% Y/Y). Over the last 2 years, SYRS has beate...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its four...
Summary Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global myelodysplastic syndrome market is expected to reach $5.6 billion by 2032; 50% o...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
2024-07-17 19:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...